Pulmonary Division
Hartford, Connecticut, 06111, United States
Location status: Recruiting
Location contact
Melanie S Collins, MD
CONTACT
Sigrid M Almeida, BS
CONTACT
NCT Number: NCT05889013
This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).
Interested in participating?
Request Info2 year and older
All sexes
Observational
Hartford, Connecticut, 06111, United States
Location status: Recruiting
Melanie S Collins, MD
CONTACT
Sigrid M Almeida, BS
CONTACT
This is an observational study to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD. Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant. These providers will then refer for enrollment in the study based on the clinical considerations for a diagnosis of PCD. Participants will be consented during the time of testing at the Pulmonary department. Any patient referred by a clinician for concerns for PCD, including those who have had PCD genetics sent, or a ciliary biopsy performed will be enrolled in the study. In addition, any participant who is referred for nasal nitric oxide testing and meets the inclusion and exclusion criteria for this testing, will also need to provide informed consent and be enrolled in the Nasal NO REDCap registry. This equipment is not currently FDA approved or CLIA certified for PCD diagnostic testing and therefore referring clinicians will be informed that the results of this test should not influence clinical decision making regarding the diagnosis of PCD. However, there is growing evidence that this testing has utility as a non-invasive screening tool for PCD and continued data from the general pediatric pulmonary population is needed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collection of already performed clinical data and nNO testing
Other names: nNO testing
Time frame: 2-3 years
To establish a research registry to characterize the features of individuals that undergo PCD diagnostic testing at Connecticut Children's Medical Center and UCONN.
Time frame: 2-3 years
To evaluate the utility of PCD diagnostic testing, including potential use of nasal nitric oxide in comparison to genetic testing and ciliary biopsy, in pulmonary practice at Connecticut Children's Medical Center and UCONN.
Time frame: 1-2 years
To refine and improve current diagnostic processes for PCD diagnosis at CCMC using information gathered from the research registry established through Primary aims 1 and 2.
Contact information is provided by the study sponsor or research team.
Melanie S Collins, MD
CONTACT
Sigrid M Almeida, BS
CONTACT
Connecticut Children's Medical Center
Other
A Clinical Study to Gather Data on the Utility of Tests That Are Used to Make a Diagnosis of Primary Ciliary Dyskinesia (PCD)
Acronym: PCD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03704207
Abnormalities, Multiple, Ciliary Motility Disorders
Nashville, Tennessee, United States
View Trial DetailsNCT07274631
Abnormalities, Multiple, Asthma
Reims, France
View Trial DetailsNCT07288827
Abnormalities, Multiple, Bronchial Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT04611516
Abnormalities, Multiple, Bronchial Diseases
Bern, Switzerland
View Trial Details